Myriad Genetics, Inc. (MYGN)Healthcare | Diagnostics & Research | Salt Lake City, United States | NasdaqGS
5.14 USD
0.00
(-0.097%) ⇩
(April 21, 2026, 12:05 p.m.
EDT)
Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ★★★☆☆ |
Hot Take | April 18, 2026, 10:16 p.m. EDT
Near-term speculative momentum is building around the $5.00 ATM level with aggressive call buying on the $5.00 strike for the immediate April expiration, yet the consensus target mean of $7.58 and the Ljung-Box p-value of ~1e-14 suggest the fairness model views current price action as statistically distant from fair value or highly erratic, warranting caution. While the SOTP analysis in recent news claims undervaluation, the company's negative operating margins, -20.8% revenue growth, and significant debt-to-equity (32.845) present a risky long-term hold despite the fresh analyst upgrade and share price spike. The stock is currently in a volatile rebound phase rather than a stable accumulation zone. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.165280 |
| MSTL | 0.197676 |
| AutoETS | 0.202439 |
| AutoARIMA | 0.202441 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.85 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.689 |
| Excess Kurtosis | -0.63 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Last Dividend Date | 2009-06-30 |
| Debt to Equity Ratio | 32.845 |
| Revenue per Share | 7.452 |
| Market Cap | 484,964,992 |
| Forward P/E | 32.35 |
| Beta | 1.64 |
| Profit Margins | -41.29% |
| Website | https://www.myriad.com |
As of April 18, 2026, 10:16 p.m. EDT: Options flow shows distinct asymmetry in positioning. For the April 17 expiration (next week), OI is heavily skewed towards 5.0 ATM calls (OTM_oi_pct: 100%), indicating strong speculative buying near current price, while OTM puts are negligible. For the May 15 and Aug 21 expirations, short-term momentum bets are evident via heavy call OI at the 6.0 and 7.0 strikes. However, medium-term protection is notable; in the May 15 expiry, there is significant Put OI at the 6.0 strike (142 OI vs 160 total), suggesting a hedge against a potential pullback from the recent highs. Implied Volatility is low for underlying expirations but elevated for near-term OTM calls (4.69 IV at 6.0 strike in April), suggesting some gamma exposure concerns or price volatility pricing in that specific strike.
| Date | Dividend | Yield % |
|---|---|---|
| 2009-07-01 | 1.75 | 6.725596 |
| 2009-06-15 | 1.75 | 5.186976 |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.30820996 |
| Address1 | 322 North 2200 West |
| All Time High | 69.0 |
| All Time Low | 1.4375 |
| Ask | 6.64 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Analyst Rating | 2.9 - Hold |
| Average Daily Volume10 Day | 1,096,880 |
| Average Daily Volume3 Month | 1,706,457 |
| Average Volume | 1,706,457 |
| Average Volume10Days | 1,096,880 |
| Beta | 1.637 |
| Bid | 3.81 |
| Bid Size | 2 |
| Board Risk | 1 |
| Book Value | 3.936 |
| City | Salt Lake City |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 3 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 5.135 |
| Current Ratio | 2.669 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 5.31 |
| Day Low | 5.0917 |
| Debt To Equity | 32.845 |
| Display Name | Myriad Genetics |
| Earnings Call Timestamp End | 1,771,882,200 |
| Earnings Call Timestamp Start | 1,771,882,200 |
| Earnings Timestamp | 1,771,880,400 |
| Earnings Timestamp End | 1,778,011,200 |
| Earnings Timestamp Start | 1,778,011,200 |
| Ebitda | -111,900,000 |
| Ebitda Margins | -0.2009 |
| Enterprise To Ebitda | -2.948 |
| Enterprise To Revenue | 0.592 |
| Enterprise Value | 329,931,968 |
| Eps Current Year | 0.044 |
| Eps Forward | 0.15874 |
| Eps Trailing Twelve Months | -3.95 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 801 584 3640 |
| Fifty Day Average | 4.7474 |
| Fifty Day Average Change | 0.38760042 |
| Fifty Day Average Change Percent | 0.08164478 |
| Fifty Two Week Change Percent | -30.820995 |
| Fifty Two Week High | 8.59 |
| Fifty Two Week High Change | -3.455 |
| Fifty Two Week High Change Percent | -0.40221184 |
| Fifty Two Week Low | 3.76 |
| Fifty Two Week Low Change | 1.3750002 |
| Fifty Two Week Low Change Percent | 0.36569154 |
| Fifty Two Week Range | 3.76 - 8.59 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 812,986,200,000 |
| Float Shares | 85,138,249 |
| Forward Eps | 0.15874 |
| Forward P E | 32.348495 |
| Free Cashflow | -46,062,500 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 2,700 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.68060994 |
| Gross Profits | 379,100,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03334 |
| Held Percent Institutions | 1.03042 |
| Implied Shares Outstanding | 94,443,029 |
| Industry | Diagnostics & Research |
| Industry Disp | Diagnostics & Research |
| Industry Key | diagnostics-research |
| Ir Website | http://investor.myriad.com/ |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Dividend Date | 1,246,406,400 |
| Last Dividend Value | 1.75 |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,238,025,600 |
| Last Split Factor | 2:1 |
| Long Business Summary | Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children's Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah. |
| Long Name | Myriad Genetics, Inc. |
| Market | us_market |
| Market Cap | 484,964,992 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_31822 |
| Most Recent Quarter | 1,609,372,800 |
| Net Income To Common | -230,000,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 485,437,169 |
| Number Of Analyst Opinions | 10 |
| Open | 5.16 |
| Operating Cashflow | -26,200,000 |
| Operating Margins | -0.2141 |
| Overall Risk | 3 |
| Payout Ratio | 0.0 |
| Peg Ratio | 1.24 |
| Phone | 801 584 3600 |
| Previous Close | 5.14 |
| Price Eps Current Year | 116.70455 |
| Price Hint | 2 |
| Price To Book | 1.304624 |
| Price To Sales Trailing12 Months | 0.87067324 |
| Profit Margins | -0.41292998 |
| Quick Ratio | 1.646 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | hold |
| Recommendation Mean | 2.91667 |
| Region | US |
| Regular Market Change | -0.0049996376 |
| Regular Market Change Percent | -0.097269215 |
| Regular Market Day High | 5.31 |
| Regular Market Day Low | 5.0917 |
| Regular Market Day Range | 5.0917 - 5.31 |
| Regular Market Open | 5.16 |
| Regular Market Previous Close | 5.14 |
| Regular Market Price | 5.135 |
| Regular Market Time | 1,776,787,521 |
| Regular Market Volume | 275,170 |
| Return On Assets | -0.07645 |
| Return On Equity | -0.23513001 |
| Revenue Growth | -0.208 |
| Revenue Per Share | 7.452 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 5 |
| Shares Outstanding | 94,443,029 |
| Shares Percent Shares Out | 0.0937 |
| Shares Short | 8,763,576 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 11,625,293 |
| Short Name | Myriad Genetics, Inc. |
| Short Percent Of Float | 0.13149999 |
| Short Ratio | 3.64 |
| Source Interval | 15 |
| State | UT |
| Symbol | MYGN |
| Target High Price | 18.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 7.58 |
| Target Median Price | 7.0 |
| Total Cash | 150,700,000 |
| Total Cash Per Share | 1.612 |
| Total Debt | 0 |
| Total Revenue | 557,000,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.95 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 6.06465 |
| Two Hundred Day Average Change | -0.92964983 |
| Two Hundred Day Average Change Percent | -0.15328994 |
| Type Disp | Equity |
| Volume | 275,170 |
| Website | https://www.myriad.com |
| Zip | 84,116 |